Biodynamik Receives FDA IDE Approval for Pivotal U.S. Trial of XT3 System in Diabetic Foot Ulcers (opens in new tab)

Biodynamik, Inc. announced FDA has approved its IDE application to initiate a pivotal clinical study evaluating the company’s XT3 System for the treatment of chronic diabetic foot ulcers.